James Budge Sells 5,907 Shares of Hinge Health (NYSE:HNGE) Stock

Posted by Geri Gentry on May 29th, 2026

Hinge Health Inc. (NYSE:HNGE – Get Free Report) CFO James Budge sold 5,907 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $53.79, for a total transaction of $317,737.53. Following the transaction, the chief financial officer directly owned 445,386 shares of the company’s stock, valued at $23,957,312.94. This represents a 1.31% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James Budge also recently made the following trade(s):

On Wednesday, May 20th, James Budge sold 781 shares of Hinge Health stock. The shares were sold at an average price of $55.34, for a total transaction of $43,220.54.
On Monday, May 11th, James Budge sold 5,906 shares of Hinge Health stock. The shares were sold at an average price of $54.82, for a total transaction of $323,766.92.
On Monday, March 23rd, James Budge sold 11,006 shares of Hinge Health stock. The shares were sold at an average price of $42.26, for a total transaction of $465,113.56.

Hinge Health Stock Up 2.1%

Shares of NYSE HNGE opened at $54.72 on Friday. Hinge Health Inc. has a twelve month low of $30.08 and a twelve month high of $62.18. The firm has a market cap of $4.23 billion and a P/E ratio of -4.43. The company has a 50 day moving average of $45.82 and a 200 day moving average of $44.59.

Hinge Health (NYSE:HNGE – Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.12 by $0.33. Hinge Health had a negative return on equity of 310.62% and a negative net margin of 78.95%.The business had revenue of $182.31 million for the quarter. During the same quarter in the prior year, the business posted $1.30 earnings per share. The business’s revenue for the quarter was up 47.2% on a year-over-year basis. As a group, equities analysts expect that Hinge Health Inc. will post 1.21 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. BIT Capital GmbH grew its position in shares of Hinge Health by 79.3% during the 4th quarter. BIT Capital GmbH now owns 3,316,101 shares of the company’s stock valued at $154,033,000 after acquiring an additional 1,466,577 shares during the period. Vanguard Group Inc. grew its position in shares of Hinge Health by 110.5% during the 4th quarter. Vanguard Group Inc. now owns 2,605,532 shares of the company’s stock valued at $121,027,000 after acquiring an additional 1,367,693 shares during the period. Tiger Global Management LLC grew its position in shares of Hinge Health by 227.1% during the 4th quarter. Tiger Global Management LLC now owns 1,805,751 shares of the company’s stock valued at $83,877,000 after acquiring an additional 1,253,743 shares during the period. Marshall Wace LLP bought a new stake in shares of Hinge Health during the 4th quarter valued at $54,469,000. Finally, Millennium Management LLC grew its position in shares of Hinge Health by 225.0% during the 4th quarter. Millennium Management LLC now owns 1,479,642 shares of the company’s stock valued at $68,729,000 after acquiring an additional 1,024,317 shares during the period.

Analyst Upgrades and Downgrades

HNGE has been the topic of several recent analyst reports. Zacks Research upgraded Hinge Health from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 13th. Stifel Nicolaus increased their target price on Hinge Health from $59.00 to $67.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Evercore restated an “outperform” rating and issued a $45.00 target price on shares of Hinge Health in a report on Wednesday, April 8th. Wells Fargo & Company lifted their target price on shares of Hinge Health from $68.00 to $80.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Finally, Royal Bank Of Canada lifted their target price on shares of Hinge Health from $55.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 6th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $67.40.

View Our Latest Analysis on Hinge Health

Hinge Health Company Profile

(Get Free Report)

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.